{
    "root": "350d8fde-4096-17eb-e063-6394a90a9984",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": {
        "text": "Diclofenac Sodium",
        "suffix": {
            "text": "Delayed Release"
        }
    },
    "value": "20250528",
    "ingredients": [
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "HYPROMELLOSES",
            "code": "3NXW29V3WO"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "METHACRYLIC ACID - METHYL METHACRYLATE COPOLYMER (1:1)",
            "code": "74G4R6TH13"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "POLYETHYLENE GLYCOL 2000",
            "code": "HAF0412YIT"
        },
        {
            "name": "POVIDONE",
            "code": "FZ989GH94E"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "DICLOFENAC SODIUM",
            "code": "QTG126297Q"
        }
    ],
    "indications": "carefully consider potential benefits risks diclofenac sodium delayed-release tablets treatment options deciding diclofenac . lowest effective dose shortest duration consistent individual patient treatment goals ( ; gastrointestinal bleeding , ulceration , perforation ) . diclofenac indicated : relief signs symptoms osteoarthritis relief signs symptoms rheumatoid arthritis acute long-term relief signs symptoms ankylosing spondylitis",
    "contraindications": "carefully consider potential benefits risks diclofenac sodium delayed-release tablets treatment options deciding diclofenac . lowest effective dose shortest duration consistent individual patient treatment goals ( ; gastrointestinal bleeding , ulceration , perforation ) . observing response initial therapy diclofenac , dose frequency adjusted suit individual patient 's needs . relief osteoarthritis , recommended 100-150 mg/day divided doses ( 50 mg twice day three times day , 75 mg twice day ) . relief rheumatoid arthritis , recommended 150-200 mg/day divided doses ( 50 mg three times day . four times day , 75 mg twice day . ) . relief ankylosing spondylitis , recommended 100-125 mg/day , administered 25 mg four times day , extra 25-mg dose bedtime necessary .",
    "warningsAndPrecautions": "diclofenac sodium delayed-release tablets 50 mg – white off-white , biconvex , round-shaped , unscored ( imprinted one side ) , supplied bottles 60 , 100 1000. bottles 60 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ndc 61442-102-60 bottles 100 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ndc 61442-102-01 bottles 1000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ndc 61442-102-10 75 mg -– white off-white , biconvex , round shaped , unscored ( imprinted one side ) , supplied bottles 60 , 100 , 500 1000. bottles 60 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ndc 61442-103-60 bottles 100 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ndc 61442-103-01 bottles 500 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ndc 61442-103-05 bottles 1000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ndc 61442-103-10 store room temperature 20°c 25°c ( 68°f 77°f ) ; excursions permitted 15°c 30°c ( 59°f 86°f ) [ usp controlled room temperature ] . protect moisture . dispense tight container ( usp ) . manufactured distributed : carlsbad technology , inc. 5923 balfour court carlsbad , ca 92008 usa revised : 07/2024 cti-11 rev . l",
    "adverseReactions": "diclofenac sodium delayed-release tablets contraindicated following patients : known hypersensitivity ( e.g . , anaphylactic serious skin ) diclofenac components product ( ; anaphylactic , serious skin ) . history asthma , urticaria , allergic-type taking aspirin nsaids . severe , sometimes fatal , anaphylactic nsaids reported patients ( ; anaphylactic reaction , exacerbation asthma related aspirin sensitivity ) . setting coronary artery bypass graft ( cabg ) surgery ( ; cardiovascular thrombotic events ) .",
    "indications_original": "Carefully consider the potential benefits and risks of diclofenac sodium delayed-release tablets and other treatment options before deciding to use diclofenac. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (\n \n  see\n  \n   WARNINGS; Gastrointestinal Bleeding, Ulceration, and Perforation\n                     ).\n\n \n                  Diclofenac is indicated:\n                  \n                     For relief of the signs and symptoms of osteoarthritis\n                     For relief of the signs and symptoms of rheumatoid arthritis\n                     For acute or long-term use in the relief of signs and symptoms of ankylosing spondylitis",
    "contraindications_original": "Carefully consider the potential benefits and risks of diclofenac sodium delayed-release tablets and other treatment options before deciding to use diclofenac. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals\n \n  (see\n  \n   WARNINGS; Gastrointestinal Bleeding, Ulceration, and Perforation)\n \n  .\n\n \n                  After observing the response to initial therapy with diclofenac, the dose and frequency should be adjusted to suit an individual patient's needs.\n                  For the relief of osteoarthritis, the recommended dosage is 100-150 mg/day in divided doses (50 mg twice a day or three times a day, or 75 mg twice a day).\n                  For the relief of rheumatoid arthritis, the recommended dosage is 150-200 mg/day in divided doses (50 mg three times a day. or four times a day, or 75 mg twice a day.).\n                  For the relief of ankylosing spondylitis, the recommended dosage is 100-125 mg/day, administered as 25 mg four times a day, with an extra 25-mg dose at bedtime if necessary.",
    "warningsAndPrecautions_original": "Diclofenac sodium delayed-release tablets\n                  \n                  50 mg – white to off-white, biconvex, round-shaped, unscored (imprinted\n \n  on one side), supplied in bottles of 60, 100 and 1000.\n\n \n                  Bottles of 60 ..................................................................NDC 61442-102-60\n                  Bottles of 100 ................................................................NDC 61442-102-01\n                  Bottles of 1000 ..............................................................NDC 61442-102-10\n                  75 mg -– white to off-white, biconvex, round shaped, unscored (imprinted\n \n  on one side), supplied in bottles of 60, 100, 500 and 1000.\n\n \n                  Bottles of 60 ..................................................................NDC 61442-103-60\n                  Bottles of 100 ................................................................NDC 61442-103-01\n                  Bottles of 500 ................................................................NDC 61442-103-05\n                  Bottles of 1000 ..............................................................NDC 61442-103-10\n                  \n                  Store at room temperature 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].\n                  \n                  Protect from moisture.\n                  \n                  \n                     Dispense in tight container (USP).\n                  \n                  \n                  Manufactured and Distributed by:\n                  \n                     Carlsbad Technology, Inc.\n                  \n                  5923 Balfour Court \n    Carlsbad, CA 92008 USA\n \n                  \n                  Revised: 07/2024 \n    CTI-11 Rev. L",
    "adverseReactions_original": "Diclofenac sodium delayed-release tablets are contraindicated in the following patients:\n                  \n                     Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to diclofenac or any components of the drug product (\n  \n   see\n   \n    WARNINGS; Anaphylactic Reactions,\n   \n    Serious Skin Reactions\n                        ).\n \n  \n                     History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients (\n  \n   see\n   \n    WARNINGS; Anaphylactic Reaction,\n   \n    Exacerbation of Asthma Related to Aspirin Sensitivity\n                        ).\n \n  \n                     In the setting of coronary artery bypass graft (CABG) surgery (\n  \n   see\n   \n    Warnings; Cardiovascular Thrombotic Events\n                        )."
}